Karl Brendel, Clare Gaynor, Cyrielle Dumont, Alexia Blesius and Marylore Chenel Using Modelling & Simulation techniques to optimise the design of a paediatric PK/PD study
|
Karl Brendel, Laetitia Canini and Marylore Chenel Population pharmacokinetics-pharmacodynamics modeling of the QTc prolongation of Moxiflovoxacin and Levofloxacin in healthy volunteers: selection of the positive control in mandatory QT/QTc studies
|
Yoon Jung Lee (1), Sriram Krishnaswami (2), Lutz Harnisch (3), Jonathan French (2), Kyungsoo Park (1) Model-based evaluation of DAS28 as a potential surrogate for ACR20 to establish the dose-response relationship for disease modifying anti-rheumatic drugs. A case study using tasocitinib (CP-690,550), an oral JAK inhibitor.
|
D Renard, CH Hsu, M Dolker, V Yu, M Looby A trial simulation example to support the design and model-based analysis of a new dose and regimen finding study
|
H. Eljebari, N. Jebabli, S. Trabelssi, I. Salouage , E. Gaies, M. Lakhal, A. Klouz Effect Of Clonidine On Bupivacaine Clearance In Tunisian Patients: Population Pharmacokinetic Investigation.
|
Martin Fink (1), Olivier Luttringer (1), Peter Gergely (2), Erik Wallstroem (2), Michael Looby (1), Goonaseelan Pillai (1) Phase I trials: Model-based assessment to identify a clinical relevant change in heart rate
|
Pinky Dua(1), Nicoletta Pons(2), Luigina Bertolotti(2), Clare Burgess(3), Roberto Gomeni(1) SB-773812: Correlation between in-silico and in-vivo metabolism
|
Tatiana Karelina(1), Oleg Demin(1), Kirill Zhudenkov(1), Dmitry Svetlichny(1), Oleg Demin Jr(1,3), David Fairman(2), and Balaji Agoram(2) Can systems modeling approach be used to understand complex PK-PD relationships? A case study of 5-lipoxygenase inhibition by zileuton
|
Elke H.J. Krekels (1,2), Saskia van Ham (1), Karel Allegaert (3), Jan de Hoon (4), Dick Tibboel (2), Meindert Danhof (1), Catherijne A.J. Knibbe (1,2,5) Paracetamol pharmacokinetics in term and preterm neonates.
|
C. Ambery(1), M. Beerahee(1) Leveraging biomarker exposure-response in drug development
|
Callies Sophie 1, Andre Valerie 2, Patel Bharvin 3, Waters David 4, Francis Paul 5, Lahn Michael 6, De Alwis Dinesh 7, Slapak Christopher 8. Integration of preclinical data to support the design of the first in-man study of LY2181308, a second generation antisense oligonucleotide.
|
I. Matthews (1), E. Pigeolet (1), G. Pillai (1), S. Balser (2), A. Berghout (2), V. Koppenburg (2), U. Kronthaler (2), I. Meyer (2) PKPD Modeling of Dose-Response & Time Course of B-Cell Depletion in Cynomolgus Monkeys
|
Anne Dubois (1), Sigrid Balser (2), Sandro Gsteiger (3), Etienne Pigeolet (3) and France Mentré (1) Model-based bioequivalence analysis of recombinant human growth hormone using the SAEM algorithm: liquid or lyophilized formulations of Omnitrope® versus original lyophilized Genotropin®
|
Iñaki F. Trocóniz1, Katja Boland2, Alexander Staab2 Population PK/PD model of the sedative effects of Flibanserin in healthy volunteers
|
C. Wang(1),(2), M.Y.M. Peeters(3), K. Allegaert(4), D. Tibboel(2), M. Danhof(1), C.A.J. Knibbe(1),(2),(3) Scaling clearance of propofol from preterm neonates to adults using an allometric model with a bodyweight-dependent maturational exponent
|
I. Ince[1,2], S.N. de Wildt[1], M.Y.M. Peeters[3], D.J. Murry[4], D. Tibboel[1], M. Danhof[2], C.A. Knibbe[1,2,3] Critical illness is a major determinant for midazolam and metabolite clearance in children
|
M.A. Boroujerdi (1), A. Facius (2), M. Danhof (1), O.E. Della Pasqua (1,3) Joint model for dropout in longitudinal trials in COPD patients
|
Johan E. Wallin(1,2), Martin Bergstrand(1), Mats O. Karlsson(1), Henryk Wilczek(3), Christine E. Staatz(1,4) Internal and external validation with sparse, adaptive-design data for evaluating the predictive performance of a population pharmacokinetic model of tacrolimus
|
Anderson JM (1,2,3) Petersson KJ (3) Friberg LE (3) Worek F (4), Thiermann H (4), Buckley NA (1,2). PK modelling of organophosphorus poisoning in humans
|
C. Piana(1), K. Adkinson(2), M. Danhof(1), , O.E. Della Pasqua(1,3) Once Daily Pharmacokinetics Of Lamivudine In HIV-Infected Children
|
R.F.W. De Cock1, M. Danhof1, K. Allegaert2, M. de Hoog3, C.A.J. Knibbe1,3,4 Predicting glomerular filtration rate using clearance of amikacin
|
Jan-Stefan Van Der Walt (1), Joe Standing (1), Mats O Karlsson (1), Per Lundborg (2), Tommy Andersson (2), Kerstin Röhss (2) and Marie Sandström (2) A population model describing the pharmacokinetics of iv esomeprazole in patients aged 0 to 17 years, inclusive
|
FT Musuamba(1), M Mourad(2), V Haufroid(3), M De Mayer(3), Capron A(1), Delattre I(1), Verbeeck R(1), Wallemacq P(1) An optimal designed study for population pharmacokinetic modeling and Bayesian estimation of Mycophenolic acid and Tacrolimus early after renal transplantation
|
Nils Hoem (1), Kristin C. Carlsson A population PK model of EPA and DHA after intake in phospholipid as well as in triglyceride form.
|
R Jelliffe(1), M Neely(1), V Ozdemir(2) Pharmacogenomics and Individualized Dosage Regimens
|